When the Summit kicks off on Monday, October 23, a panel of leaders will spare little time before diving into the most pressing question in precision medicine: How are we paying for this?
In a time of value-based care, genomic testing can be expensive, especially if we want to scale these tests to healthy populations. Yet, these tests may hold the keys to managing and eliminating some of the most debilitating diseases. So who should foot the first bill? As government and insurance companies weigh the costs and benefits, consumers may be the first to take the plunge. The recent FDA approval
of consumer genetic tests is opening the door to a new age of medicine. Consumers are demanding care due to their own findings and interpretations, regardless of a doctor’s recommendation. All of these possibilities brought on by genomic testing have clinicians, insurance companies, and government leaders reflecting on payment strategies, all in the midst of debates about keeping care affordable.
On October 23, attendees will get a glimpse of how these stakeholders are planning to react to these pressures, how they can collaborate to ensure better care and lower costs, and how genomics companies can successfully navigate a market that resides on the cutting, yet uncertain, edge of innovation. We hope you can join us.
Hype, Hope, and the Bottom Line: Reimbursement Strategies for Genomic Innovation
October 23, 2017 | 2:30pm – 3:25pm
, CMO, Express Scripts
Phil Febbo, MD
, Chief Medical Officer, Genomic Health, Inc.
Alan Wright, MD
, CMO, Roche Diagnostics
EVP, Reimbursement, Myriad
David Flannery, MD
, Medical Director, American College Medical Genetics and Genomics